Truxillic acid monoamides as fatty acid binding protein 5 inhibitors
Bioorganic & Medicinal Chemistry · 2023-10 · 94 · 117464
DOI: 10.1016/j.bmc.2023.117464 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2023-10. Verfasst von Chuanzhou Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Stony Brook University, Stony Brook, NY, USA. Hauptthemen laut MEDLINE: Fatty Acid-Binding Proteins, Analgesics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
Fatty acid binding proteins (FABPs) are intracellular chaperones that deliver bioactive lipids to cytosolic enzymes and nuclear receptors, thereby regulating diverse biological functions. FABP5 is a member of the FABP family that mediates endocannabinoid transport and inactivation, with pharmacological or genetic FABP5 inhibition conferring antinociceptive effects. Consequently, FABP5 inhibitors have emerged as promising analgesics and demonstrate antinociceptive activity in models of pain. Recently developed FABP5 inhibitors based upon the α-truxillic acid monoester (TAME) scaffold demonstrate high affinities for FABP5 but are commonly accompanied by reduced selectivity against related FABPs, notably FABP3 that is expressed in the heart, highlighting the need to identify additional scaffolds that afford enhanced selectivity while maintaining FABP5 potency. Here, we describe the synthesis and biological evaluation of truxillic acid monoamides (TAMADs) as potent, selective, and efficacious FABP5 inhibitors. Combining in silico molecular docking and in vitro binding assay approaches, our findings demonstrate that TAMADs exhibit exceptional selectivity against FABP3 and several compounds attain high FABP5 affinities. Examination of antinociceptive activity revealed that TAMADs and their corresponding TAMEs demonstrate comparable efficacy and temporal activity profiles in vivo. These results position TAMAD as a suitable scaffold for the development of FABP5 inhibitors with diminished FABP3 cross-reactivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Stony Brook University, Stony Brook, NY, USA.
- Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
- Department of Chemistry, Stony Brook University, Stony Brook, NY, USA; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, USA. Electronic address: Iwao.Ojima@Stonybrook.edu.
- Department of Anesthesiology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA; Institute of Chemical Biology and Drug Discovery, Stony Brook University, Stony Brook, NY, USA; Stony Bro…
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIDA NIH HHS
Zitieren
APA
Zhu, C., Schutz, L., Jayanetti, K., Takemura, K., Doswell, F., Wang, L., Ojima, I., & Kaczocha, M. (2023). Truxillic acid monoamides as fatty acid binding protein 5 inhibitors. Bioorganic & Medicinal Chemistry, 94, 117464. https://doi.org/10.1016/j.bmc.2023.117464
Vancouver
Zhu C, Schutz L, Jayanetti K, Takemura K, Doswell F, Wang L, et al. Truxillic acid monoamides as fatty acid binding protein 5 inhibitors. Bioorganic & Medicinal Chemistry. 2023;94:117464. doi:10.1016/j.bmc.2023.117464
BibTeX
@article{Zhu2023,
author = {Zhu, Chuanzhou and Schutz, Livia and Jayanetti, Kalani and Takemura, Kathryn and Doswell, Faniya and Wang, Liqun and Ojima, Iwao and Kaczocha, Martin},
title = {Truxillic acid monoamides as fatty acid binding protein 5 inhibitors},
journal = {Bioorganic & Medicinal Chemistry},
year = {2023},
volume = {94},
pages = {117464},
doi = {10.1016/j.bmc.2023.117464}
}
EUVIMED